Dow Jones

39 308,00

-0,06%

DAX

Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

Accueil
Investir
Actions
Canadá
CSE
Algernon Pharmaceuticals Inc (AGN)
Algernon Pharmaceuticals Inc (AGN) Actualités

AGN

Algernon Pharmaceuticals (AGN)

Algernon Pharmaceuticals Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:CSE:AGN

Date	Heure	Source	Titre	Symbole	Société
11/02/2021	14h00	InvestorsHub NewsWire	Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol	CSE:AGN	Algernon Pharmaceuticals Inc
04/06/2020	18h41	InvestorsHub NewsWire	Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19	CSE:AGN	Algernon Pharmaceuticals Inc
13/04/2020	15h44	InvestorsHub NewsWire	Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard	CSE:AGN	Algernon Pharmaceuticals Inc
13/03/2020	13h40	InvestorsHub NewsWire	Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency	CSE:AGN	Algernon Pharmaceuticals Inc
06/03/2020	14h32	InvestorsHub NewsWire	Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus	CSE:AGN	Algernon Pharmaceuticals Inc
31/07/2019	13h22	InvestorsHub NewsWire	Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...	CSE:AGN	Algernon Pharmaceuticals Inc
29/07/2019	14h32	InvestorsHub NewsWire	Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...	CSE:AGN	Algernon Pharmaceuticals Inc
03/07/2019	15h06	InvestorsHub NewsWire	Algernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%	CSE:AGN	Algernon Pharmaceuticals Inc
04/06/2019	14h00	InvestorsHub NewsWire	Q&A with Christopher J. Moreau CEO of Algernon Pharmaceuticals	CSE:AGN	Algernon Pharmaceuticals Inc
28/05/2019	14h00	InvestorsHub NewsWire	Algernon Pharmaceuticals: Join us for an interview with the CEO and CSO	CSE:AGN	Algernon Pharmaceuticals Inc
23/05/2019	14h04	InvestorsHub NewsWire	Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD	CSE:AGN	Algernon Pharmaceuticals Inc